Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

@article{Ptaszynska2014SafetyPO,
  title={Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events},
  author={Agata Ptaszynska and Kristina M. Johnsson and Shamik J. Parikh and T.W.A. de Bruin and Anne Marie Apanovitch and James F. List},
  journal={Drug Safety},
  year={2014},
  volume={37},
  pages={815-829}
}
BackgroundDapagliflozin reduces hyperglycaemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion.ObjectivesThis study determined the overall safety profile of dapagliflozin in T2DM.MethodsSafety of dapagliflozin in pooled analyses of phase IIb/III studies was evaluated. Patients received comparator or dapagliflozin as monotherapy, add-on to antidiabetic therapy, or as initial combination with metformin. Proportions of patients with adverse events (AEs) and… Expand
The Effect and Safety of Dapagliflozin in Patients with Type 2 Diabetes: A Single-Institution Pharmacovigilance Review
TLDR
Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, lowers blood glucose by reducing glucose reabsorption at the proximal renal tubule in an insulin-independent manner and adverse drug events observed were lower urinary tract symptoms, dehydration-related symptoms, and urogenital infection. Expand
Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
  • D. Hinnen
  • Medicine
  • Therapeutic advances in endocrinology and metabolism
  • 2015
TLDR
Evidence from clinical trials suggests that dapagliflozin is a promising new treatment option for type 2 diabetes mellitus, and a long-term cardiovascular outcomes study is ongoing. Expand
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials
TLDR
This analysis of pooled safety data based on more than 15,000 patient-years’ exposure supports a favorable benefit–risk profile of empagliflozin in patients with T2DM. Expand
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
TLDR
The 104-week safety study of dapagliflozin in older patients with type 2 diabetes mellitus found no change in general safety or cardiovascular safety, and the frequency of adverse events and discontinuations was similar across age groups. Expand
Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study
TLDR
Dapagliflozin was found to be a well tolerated and effective treatment option for T2DM patients in Saudi Arabia and the mean HbA1c level significantly decreased during the observation period compared to baseline. Expand
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
TLDR
Empagliflozin was not associated with an increased risk of hypoglycemia versus placebo, except in patients on background sulfonylurea and/or insulin, and well tolerated in patients with T2DM. Expand
Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
TLDR
In this study that evaluated T2D patients who were at high risk for future CVD events, dapagliflozin administration had significantly greater effects in reducing HbA1c, BW, and SBP, without adversely impacting CV safety when compared with placebo treatment. Expand
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures
TLDR
Using the recently adjusted and currently accepted diabetes-related QMs, this analysis observed superior glycemic control with canagliflozin compared with maximally tolerated glimepiride in patients with T2DM who were previously poorly controlled on metformin monotherapy. Expand
Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
  • Huang-Ping Yu, V. Woo
  • Medicine
  • Diabetes, metabolic syndrome and obesity : targets and therapy
  • 2017
TLDR
Dapagliflozin/saxagliptin combination is generally well tolerated and is an effective tool in helping patients with diabetes improve glycemic control. Expand
Durability of response to dapagliflozin: a review of long-term efficacy and safety
  • S. Jabbour
  • Medicine
  • Current medical research and opinion
  • 2017
TLDR
The findings of long-term studies indicate that dapagliflozin is effective as monotherapy and in combination with other anti-hyperglycemic agents, including insulin and oral anti-diabetic therapies, in improving glycemic control and reducing blood pressure and weight for up to 4 years. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers
TLDR
In patients receiving high insulin doses plus insulin sensitizers who had their baseline insulin reduced by 50%, dapagliflozin decreased A1C, produced better FPG and PPG levels, and lowered weight more than placebo. Expand
[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
TLDR
Despite similar 52-week glycemic efficacy, dapagliflozin reduced weight and produced less hypoglycemia than glipizide in type 2 diabetes inadequately controlled with metformin. Expand
Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
TLDR
Dapagliflozin improves glycemic control, stabilizes insulin dosing, and reduces weight without increasing major hypoglycemic episodes in patients with inadequately controlled type 2 diabetes mellitus. Expand
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
TLDR
In patients with type 2 diabetes inadequately controlled on piog litazone, the addition of dapagliflozin further reduced HbA1c levels and mitigated the pioglitazone-related weight gain without increasing hypoglycemia risk. Expand
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
TLDR
Addition of dapagliflozin to meetformin provides a new therapeutic option for treatment of type 2 diabetes in patients who have inadequate glycaemic control with metformin alone. Expand
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise
TLDR
The near absence of hypoglycemia and an insulin-independent mechanism of action make dapagliflozin a unique addition to existing treatment options for type 2 diabetes. Expand
Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin
TLDR
The co-administration of dapagliflozin and simvastatin, valsartan, warfarin, or digoxin was well tolerated without clinically meaningful drug-drug interaction. Expand
Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study
TLDR
Dapagliflozin, at supratherapeutic doses, does not have a clinically significant effect on the QT interval in healthy subjects. Expand
Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
TLDR
The results suggest that in patients with type 2 diabetes, inadequately controlled on sitagliptin with or without metformin, add-on treatment with dapagliflozin provides additional clinical benefit and is well tolerated. Expand
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
TLDR
Dapagliflozin improved hyperglycemia and facilitates weight loss in type 2 diabetic patients by inducing controlled glucosuria with urinary loss of ∼200–300 kcal/day and demonstrated significant glycemic improvements versus placebo. Expand
...
1
2
3
4
...